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Abstract
Bedaquiline, a potent new therapy for drug-resistant tuberculosis, results in improved survival 
including in HIV patients with multidrug and extensively drug-resistant tuberculosis. In line with 
WHO recommendations, in South Africa and other low-income and middle-income settings, 
antiretroviral therapy is switched from generic fixed-dose combination efavirenz-containing 
regimens to twice-daily nevirapine with separate companion pills because of interactions between 
efavirenz and bedaquiline. Early data suggest a signal for low antiretroviral therapy adherence 
after this antiretroviral therapy switch. Mortality and other tuberculosis-specific benefits noted 
with bedaquiline treatment in multidrug and extensively drug-resistant tuberculosis HIV might be 
compromised by HIV viral failure, and emergent antiretroviral resistance. Programmatic 
responses, such as adherence support and dual pharmacovigilance, should be instituted; 
antiretroviral therapy initiation with fixed-dose combinations without bedaquiline drug 
interactions should be strongly considered.
Introduction
In 2006, an outbreak of extensively drug-resistant tuberculosis in patients with HIV in 
Tugela Ferry, in rural KwaZulu-Natal, South Africa drew unprecedented global attention 
because of severe early mortality1 and the potential for transmission of an apparently 
untreatable strain of tuberculosis in a community with a high burden of HIV.2 While the 
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world’s focus was on the emergence of this highly drug-resistant tuberculosis strain, the 
rapid mortality of the patients in Tugela Ferry (median survival 16 days from extensively 
drug-resistant tuberculosis diagnosis) was a result, at least in part, of their advanced and 
untreated HIV/AIDS (median CD4 count 63 cells per μL).1
Bedaquiline, a robust and effective new diarylquinoline antimycobacterial,3 is the first new 
tuberculosis drug approved for the treatment of multidrug and extensively drug-resistant 
(MXDR) tuberculosis in more than 40 years.4 An operational study of treatment for MXDR 
tuberculosis with bedaquiline-containing regimens in programmatic settings in South Africa 
has shown a three-times reduction in mortality over about 18 months compared with patients 
with older, injectable-based treatment regimens.5 In this operational cohort, 1899 (70·8%) of 
13 893 patients were co-infected with HIV and 11 729 (89·5%) of those patients were 
treated with antiretroviral therapy (ART).5 In this study and others, the effect of bedaquiline 
introduction in the treatment of patients co-infected with HIV and MXDR tuberculosis, on 
HIV-specific factors such as ART adherence, CD4 T-cell count and HIV viral load were not 
reported.
Treatment of tuberculosis in patients on ART
About 13% of incident tuberculosis cases globally (or about 1·2 million cases) occur in HIV 
co-infected patients.6 In South Africa, there are approximately 11 000 incident cases of 
MXDR tuberculosis (new and retreatment) in people with HIV each year.6 One of the most 
common first-line ART regimens, in South Africa and other low-income and middle-income 
countries (LMICs), is a once-daily, fixed-dose, combination pill including the non-
nucleoside reverse transcriptase inhibitor, efavirenz, with a dual non-nucleoside reverse 
transcriptase inhibitor, tenofovir disoproxil fumarate and emtricitabine backbone.7 This 
fixed-dose combination is well tolerated, effective, and affordable.7,8
Bedaquiline is hepatically metabolised by the cytochrome p450 isoenzyme 3A (CYP3A) to 
its active M2 metabolite, which has reduced antimycobacterial activity but might result in a 
QT-prolonging effect.9 However, efavirenz induces CYP3A, leading to reduced bedaquiline 
concentrations with coadministration.4,9 In an AIDS Clinical Trials Group study of 30 
healthy volunteers, coadministration of efavirenz with a single dose of bedaquiline led to an 
18% reduction in the bedaquiline area under the curve.10 A subsequent study used these data 
in pharmacometric models that accounted for bedaquiline’s very long terminal half-life (5·5 
months), and reductions in steady-state exposures were estimated to be around 50% with 
efavirenz coadministration.11 In the same paper, lopinavir boosted with ritonavir, a potent 
CYP3A inhibitor, was estimated to decrease clearance of bedaquiline by 35% and its active 
M2 metabolite by 58%. Proposed model-based alternative dosing schemes might mitigate 
drug interactions, but the recommended regimens have not been tested prospectively to 
assess pharmacokinetics and safety or to evaluate costs.11
In response to these pharmacokinetic and modelling data, the primary WHO guidance is to 
change the ART regimen from efavirenz to nevirapine when bedaquiline is started (panel), 
because nevirapine has modest effect on bedaquiline concentrations.12,13 Boosted protease 
inhibitors are discouraged in WHO guidance because there is concern that build-up of 
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bedaquiline and toxic metabolites could lead to increased adverse effects, particularly 
cardiotoxicity.13 In LMIC settings, extended-release nevirapine or nevirapine-based fixed-
dose combinations are generally not available (likely due to the twice-daily dose) and 
therefore nevirapine-based ART regimens include three different medications and require 
twice-daily dosing.
To date, ART switching has been primarily studied in the context of simplifying ART 
regimens (eg, changing to fixed-dose combination) to improve adherence14 or the side-effect 
profile (eg, lipodystrophy).15 However, switching from an efavirenz-based fixed-dose 
combination to a second-line ART regimen consisting of multiple pills given twice daily 
might negatively effect ART adherence.14 In one meta-analysis, use of daily ART fixed-dose 
combinations was associated with 17% improved adherence compared with treatment with 
separate twice-daily pills (and a 9% absolute improvement in rates of HIV viral load 
suppression).16 This adherence benefit with fixed-dose combinations has been reproduced in 
multiple populations and settings.16,17 Many patients being treated for MXDR tuberculosis 
and HIV are taking eight or more medications and, therefore, adding to the pill burden might 
reduce overall medication adherence because of the increased regimen complexity and 
treatment fatigue.18 Compared with efavirenz-containing regimens, nevirapine has been 
associated with higher rates of HIV virological failure in some, though not all, studies.16,19 
There was a reported pooled estimate of 15% increased risk of virological failure in another 
meta-analysis.20 Neviripine has a more severe side-effect profile (rash and 
hepatotoxicity)21,22 and has been associated with an increased risk for ART discontinuation.
22,23
To understand these issues in more depth, we have begun a study of treatment adherence in 
patients co-infected with MXDR tuberculosis and HIV, initiating treatment with bedaquiline 
in those receiving ART in KwaZulu-Natal, South Africa. The PRAXIS study 
(NCT03162107) uses an electronic monitoring device (Wisepill RT2000) to measure real-
time adherence to bedaquiline and ART.24,25 We expect that qualitative interviews in the 
PRAXIS cohort might help to define the effect of ART switching on adherence behaviour.
Bedaquiline-containing regimens are associated with reduced mortality, quicker time to 
sputum culture conversion, and higher MXDR-tuberculosis treatment success, including in 
patients with HIV. However, it is important to also consider HIV-specific outcomes. If 
switching ART from an efavirenz fixed-dose combination to multiple-pill, twice-daily 
nevirapine-based regimens results in decreased adherence leading to worsened HIV viral 
control, then the overall benefit of bedaquiline might be compromised. Suboptimal ART 
adherence (whether because of increased pill burden or nevirapine-associated adverse drug 
effects) might also select for resistance to non-nucleoside reverse transcriptase inhibitors.
There are several programmatic responses that should be considered by tuberculosis and 
HIV programmes that treat patients with MXDR tuberculosis and HIV with bedaquiline-
containing regimens. In addition to tuberculosis-related pharmacovigilance, commensurate 
levels of HIV-specific pharmacovigilance should be practiced. Adherence to HIV 
medications should be reevaluated and supported, with specific attention to patient support 
and treatment literacy, especially when switching ART regimens. Research is needed to 
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identify evidence-based interventions to improve adherence and support patients in dealing 
with dual stigma, depression, and other mental health issues including substance abuse.26 
Testing of alternative ART regimens is needed including more affordable fixed-dose 
combinations of nevirapine formulations. Increased bedaquiline dosing with efavirenz fixed-
dose combinations should also be studied to determine if augmented dosing delivers 
appropriate bedaquiline concentrations without increased adverse effects. An additional 
consideration is that the estimated population prevalence of non-nucleoside reverse 
transcriptase inhibitor drug-resistance in previously untreated HIV infected patients is 10·1% 
in Southern Africa, just above the point where WHO guidance recommends considering a 
non-nucleoside reverse transcriptase inhibitor for first-line regimen.27
Dolutegravir, an integrase strand transfer inhibitor, is increasingly being championed as first-
line ART globally.28 Dolutegravir fixed-dose combination has also been identified as a 
central component of a potential companion ART regimen for treatment of MXDR 
tuberculosis and HIV co-infection because it is well tolerated and, based on knowledge of 
drug metabolic pathways, there is a low theoretical risk of drug interactions. Generic 
dolutegravir-containing fixed-dose combinations will probably become available in the near 
future in South Africa. Ongoing trials are providing dolutegravir-based ART with 
bedaquiline-containing regimens, so preliminary pharmacokinetic data might be available 
soon.28 However, we note the recent concerns raised by the Tsepamo study about the 
potential for increased risk of neural-tube defects in women who become pregnant while on 
dolutegravir,29 which would require its provision to reproductive-age women to be 
accompanied with appropriate counselling and contraceptives.
Conclusion
Bedaquiline is a crucial advance in the treatment of MXDR tuberculosis. Operational roll-
out in South Africa has been an unmitigated success especially given the substantial 
challenges associated with diagnosis, patient selection, and monitoring. However, enhanced 
attention to the HIV component of HIV-associated MXDR tuberculosis is important, to 
prevent adverse HIV-associated outcomes such as loss of virological control, emergence of 
drug resistance, and severe toxic effects that can erode gains noted with bedaquiline 
treatment. To sustain and extend this success, we caution against ART switches that 
substantively increase patient burden (eg, multipill, multidose regimens as presently required 
for nevirapine-based therapy). Pharmacovigilance, enhanced treatment support, and 
increased medication literacy, particularly around dual adherence to new drugs for 
multidrug-resistant tuberculosis and changes to ongoing ART must accompany treatment.18 
Development and testing of new companion ART regimens is urgently needed to maximise 
the benefits of bedaquiline in patients with HIV who have MXDR tuberculosis.
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Recommendations for ART and bedaquiline
2014 WHO recommendations for ART regimens for individuals on bedaquiline12
• Nevirapine with two NRTIs (eg, zidovudine with lamivudine or emtricitabine 
or tenofovir with lamivudine or emtricitabine)
• Triple NRTI (eg, zidovudine with lamivudine or emtricitabine, and abacavir); 
this option should only be used when others are not possible)
General considerations for WHO recommendations
• Avoid regimens with protease inhibitors
• Conduct monthly monitoring for QT interval prolongation
• Be aware of potential liver toxicity with nevirapine and bedaquiline
• These WHO recommendations might be superseded. Please consult current 
guidance
Proposed alternative recommendations for ART regimens for individuals on 
bedaquiline
• NRTI, no drug interactions anticipated; triple NRTI regimen not 
recommended
• Efavirenz, 50% reduction in bedaquiline with efavirenz anticipated; avoid 
coadministration, doubling of bedaquiline dose might mitigate drug-drug 
interaction, but has not been tested clinically and is costly
• Nevirapine, no drug–drug interaction; use with caution with high CD4, and 
pill burden, possibly less effective, consider monitoring hepatic function; 
monitor and support adherence
• Protease inhibitor, increased bedaquiline, might or might not be increased M2 
metabolite, monitor QTc closely; higher QT possible, not confirmed in large 
studies
• Dolutegravir, no drug interactions anticipated; drug of choice where available, 
counsel sexually active female patients
General considerations for alternative regimens
• Adherence support and monitoring around tuberculosis and ART
• Be aware that increased pill burden and toxicity could make adherence more 
challenging
• Monthly sputum tuberculosis culture results and periodic HIV viral load to 
monitor treatment response
• HIV and tuberculosis sequencing to identify amplification of resistance on 
treatment.
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• Conduct monthly monitoring for QTc interval prolongation
ART=antiretroviral therapy. NRTI=nucleoside or nucleotide reverse transcriptase 
inhibitor.
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